Announced details
Non-erosive gastroesophageal reflux disease (NERD), erosive esophagitis (EE) and gastroesophageal reflux disease (GERD)
Percentage of days without 24-hour heartburn through Week 4 of the NERD trial: placebo, 17.3%; tegoprazan 50 mg, 26.2%; 100 mg, 30.1%. Percentage of days without nocturnal heartburn: placebo, 27.0%; 50 mg, 36.1%; 100 mg, 39.9%. Among confirmed GERD cases in the EE trial, the EE healing rate at Week 2 was 75.4% versus 60.7%, and the cumulative rate at Week 8 was 83.4% versus 72.7%.
Cumulative sales in South Korea based on outpatient prescriptions exceeded ¥1 trillion in April 2026. Tegoprazan products are sold in 20 countries. Business activities, including development, manufacturing and sales, are conducted in 57 countries worldwide. A separate document states that marketing approval has been obtained in 24 countries worldwide.
In September 2010, the Company entered into an exclusive license agreement with CJ HealthCare Corporation (now HK inno.N Corporation) covering tegoprazan in East Asia, and expanded the partnership to North America and Europe in November 2019. In December 2021, HK inno.N Corporation entered into a license agreement with Braintree Laboratories, Inc. covering exclusive development, manufacturing and commercialization rights in the United States and Canada. The Company is entitled to receive a portion of the revenue received by HK inno.N Corporation from its partners.
HK inno.N Corporation: headquartered in Osong, South Korea. Sebela Pharmaceuticals Inc.: headquartered in the state of Georgia, United States. Braintree Laboratories, Inc.: a division of the Sebela Pharmaceuticals group, with locations including Braintree, Massachusetts, United States, and Dublin, Ireland. It conducts research and development, manufacturing and commercialization of treatments in the gastrointestinal field.
ACG Presidential Award
American College of Gastroenterology（ACG）
TRIUMpH-NERD trial: NCT05587322; TRIUMpH-EE trial: NCT05587309. Other information: Not disclosed
HK inno.N Corporation: Osong, South Korea. Sebela Pharmaceuticals Inc.: state of Georgia, United States. Braintree Laboratories, Inc.: Braintree, Massachusetts, United States; Dublin, Ireland; and other locations
The Company will receive no upfront payment in connection with this matter. The Company believes that it will contribute to enhancing value over the medium to long term.
The company does not address Contract Value / Offering price.
American College of Gastroenterology 2026 Annual Scientific Meeting, Lyon Consensus 2.0, Wakefield Research (Data on File, Braintree Laboratories, Inc., 2026), and other sources
| Item | Details |
|---|---|
| Names of Products / Services Covered | Tegoprazan (marketed as K-CAB®) / TRIUMpH-NERD trial and TRIUMpH-EE trial |
| Counterparty | HK inno.N Corporation、Sebela Pharmaceuticals Inc.、Braintree Laboratories, Inc. |
| Counterparty overview | HK inno.N Corporation: headquartered in Osong, South Korea. Sebela Pharmaceuticals Inc.: headquartered in the state of Georgia, United States. Braintree Laboratories, Inc.: a division of the Sebela Pharmaceuticals group, with locations including Braintree, Massachusetts, United States, and Dublin, Ireland. It conducts research and development, manufacturing and commercialization of treatments in the gastrointestinal field. |
| Relationship with the Company | In September 2010, the Company entered into an exclusive license agreement with CJ HealthCare Corporation (now HK inno.N Corporation) covering tegoprazan in East Asia, and expanded the partnership to North America and Europe in November 2019. In December 2021, HK inno.N Corporation entered into a license agreement with Braintree Laboratories, Inc. covering exclusive development, manufacturing and commercialization rights in the United States and Canada. The Company is entitled to receive a portion of the revenue received by HK inno.N Corporation from its partners. |
| Contract Date | September 2010, November 2019 and December 2021 |
| Launch date | 2019 (launched in South Korea as K-CAB®, with actual sales recorded) |
| Applicable area | Non-erosive gastroesophageal reflux disease (NERD), erosive esophagitis (EE) and gastroesophageal reflux disease (GERD) |
| Award/certification name | ACG Presidential Award |
| Awarding / certifying body | American College of Gastroenterology（ACG） |
| Registration number and expiry date | TRIUMpH-NERD trial: NCT05587322; TRIUMpH-EE trial: NCT05587309. Other information: Not disclosed |
| Location | HK inno.N Corporation: Osong, South Korea. Sebela Pharmaceuticals Inc.: state of Georgia, United States. Braintree Laboratories, Inc.: Braintree, Massachusetts, United States; Dublin, Ireland; and other locations |
| Quantitative Effects | Percentage of days without 24-hour heartburn through Week 4 of the NERD trial: placebo, 17.3%; tegoprazan 50 mg, 26.2%; 100 mg, 30.1%. Percentage of days without nocturnal heartburn: placebo, 27.0%; 50 mg, 36.1%; 100 mg, 39.9%. Among confirmed GERD cases in the EE trial, the EE healing rate at Week 2 was 75.4% versus 60.7%, and the cumulative rate at Week 8 was 83.4% versus 72.7%. |
| Usage history | Cumulative sales in South Korea based on outpatient prescriptions exceeded ¥1 trillion in April 2026. Tegoprazan products are sold in 20 countries. Business activities, including development, manufacturing and sales, are conducted in 57 countries worldwide. A separate document states that marketing approval has been obtained in 24 countries worldwide. |
| Impact on Business Performance | The Company will receive no upfront payment in connection with this matter. The Company believes that it will contribute to enhancing value over the medium to long term. |
| Source | American College of Gastroenterology 2026 Annual Scientific Meeting, Lyon Consensus 2.0, Wakefield Research (Data on File, Braintree Laboratories, Inc., 2026), and other sources |
Items this document does not state (3)
These are items the company does not state in this document. We do not leave them blank, nor fill them in from other sources or by inference.
The reasons the company gives
The company's own explanation, not something inferred from the numbers.The trial results were presented at ACG 2026. The Company explained that this represents important progress in the development of tegoprazan's business in the United States and will contribute to enhancing value over the medium to long term.